Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech binary events -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (123)	10/7/2003 5:46:53 PM
From: Icebrg	Read Replies (1) \| Respond to of 295

>>NPSP, March(?) '04>> I don't think that will be very binary. We already more or less know from the PATH study that the stuff works. The current studies will just define how well it does. Forteo, which is a very similar drug, has already been approved etc. The only binary thing around here, that I am aware of is the preclinical study of certain cancer "risks". Forteo had some rats with cancer, if Preos does better it would truly be binary. If not, I don't think it will matter much as Forteo also had those problems. Erik